D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder

被引:137
|
作者
Storch, Eric A. [1 ]
Merlo, Lisa J.
Bengtson, Michael
Murphy, Tanya K.
Lewis, Mark H.
Yang, Mark C.
Jacob, Marni L.
Larson, Michael
Hirsh, Adam
Fernandez, Melanie
Geffken, Gary R.
Goodman, Wayne K.
机构
[1] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pediat, Gainesville, FL 32610 USA
[3] Univ Florida, Dept Stat, Gainesville, FL 32610 USA
[4] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA
关键词
D-cycloserine; exposure-response prevention therapy; obsessive-compulsive disorder; treatment;
D O I
10.1097/YIC.0b013e32819f8480
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obsessive-compulsive disorder is a common, chronic, and oftentimes disabling disorder. The only established first-line treatments for obsessive-compulsive disorder are exposure and response prevention therapy and the serotonin reuptake inhibitors. Many patients do not experience complete symptom resolution with either modality and require augmentation approaches. Recent animal and clinical data suggest that D-cycloserine, a partial agonist that acts at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate receptor complex, may enhance extinction learning that occurs in exposure-based psychotherapies. Given this, this study examined if D-cycloserine (250 mg) enhances the overall efficacy and rate of change of exposure and response prevention therapy for adult obsessive-compulsive disorder. Participants were 24 adults meeting Diagnostic and Statistical Manual of Mental Disorders-IV criteria for obsessive-compulsive disorder. The study design was a randomized, double-blinded, placebo-controlled augmentation trial examining exposure and response prevention therapy+ D-cycloserine versus exposure and response prevention therapy+ placebo. All patients received 12 weekly sessions of exposure and response prevention treatment. The first session involved building a ritual hierarchy and providing psychoeducation about obsessive-compulsive disorder. The second session involved a practice exposure. Sessions 3-12 involved exposure and response prevention exercises. D-cycloserine or placebo (250 mg) was taken 4 h before every session. No significant group differences were found across outcome variables. The rate of improvement did not differ between groups. The present results fail to support the use Of D-cycloserine with exposure and response prevention therapy for adult obsessive-compulsive disorder. As this study is the first to explore this question and a number of methodological issues must be considered when interpreting the findings, the conclusions that may be drawn from our results are limited.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 50 条
  • [1] D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder (vol 22, pg 230, 2007)
    Storch, E. A.
    Merlo, L., I
    Bengtson, M.
    Murphy, T. K.
    Lewis, M. H.
    Yang, M. C.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (05) : 312 - 312
  • [2] D-cycloserine augmented exposure therapy for obsessive-compulsive disorder
    Kushner, Matt G.
    Kim, Suck Won
    Donahue, Christopher
    Thuras, Paul
    Adson, David
    Kotlyar, Michael
    McCabe, James
    Peterson, Jillian
    Foa, Edna B.
    BIOLOGICAL PSYCHIATRY, 2007, 62 (08) : 835 - 838
  • [3] Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder
    Wilhelm, Sabine
    Buhlmann, Ulrike
    Tolin, David F.
    Meunier, Suzanne A.
    Pearlson, Godfrey D.
    Reese, Hannah E.
    Cannistraro, Paul
    Jenike, Michael A.
    Rauch, Scott L.
    AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (03): : 335 - 341
  • [4] Advances in the treatment of pediatric obsessive-compulsive disorder: rationale and design for the evaluation of D-cycloserine with exposure and response prevention
    McGuire, Joseph F.
    Lewin, Adam B.
    Geller, Daniel A.
    Brown, Ashley
    Ramsey, Kesley
    Mutch, Jane
    Mittelman, Andrew
    Micco, Jamie
    Jordan, Cary
    Wilhelm, Sabine
    Murphy, Tanya K.
    Small, Brent J.
    Storch, Eric A.
    NEUROPSYCHIATRY, 2012, 2 (04) : 291 - 300
  • [5] D-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder
    de Leeuw, A. S.
    van Megen, H. J. G. M.
    Kahn, R. S.
    Westenberg, H. G. M.
    EUROPEAN PSYCHIATRY, 2017, 40 : 38 - 44
  • [6] D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis
    Xia, Jing
    Du, Yanqiu
    Han, Jiyang
    Liu, Guo
    Wang, Xumei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2101 - 2117
  • [7] D-Cycloserine for Treatment Nonresponders With Obsessive-Compulsive Disorder: A Case Report
    Norberg, Melissa M.
    Gilliam, Christina M.
    Villavicencio, Anna
    Pearlson, Godfrey D.
    Tolin, David F.
    COGNITIVE AND BEHAVIORAL PRACTICE, 2012, 19 (02) : 338 - 345
  • [8] Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder A Randomized Clinical Trial
    Kvale, Gerd
    Hansen, Bjarne
    Hagen, Kristen
    Abramowitz, Jonathan S.
    Bortveit, Tore
    Craske, Michelle G.
    Franklin, Martin E.
    Haseth, Svein
    Himle, Joseph A.
    Hystad, Sigurd
    Kristensen, Unn Beate
    Launes, Gunvor
    Lund, Anders
    Solem, Stian
    Ost, Lars-Goran
    JAMA NETWORK OPEN, 2020, 3 (08)
  • [9] Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder
    Rothbaum, Barbara Olasov
    AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (03): : 293 - 296
  • [10] Does D-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?
    Park, Jennifer M.
    Small, Brent J.
    Geller, Daniel A.
    Murphy, Tanya K.
    Lewin, Adam B.
    Storch, Eric A.
    JOURNAL OF CHILD AND FAMILY STUDIES, 2014, 23 (05) : 863 - 871